Cipla Limited has informed the Exchange regarding a revised press release dated December 15, 2023, titled "Revised Press Release - This is further to the press release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised press release on the said matter.